Newsroom | 18316 results

Sorted by: Latest
Genetics
-

台灣原創SNQ認證機制躍上國際 攜手ICHOM引領亞太醫療品質標準

台北--(BUSINESS WIRE)--(美國商業資訊)-- 在台灣推動28年的SNQ國家品質標章，12月6日在「亞太醫療品質年會」上，由總召集人陳維昭，與國際健康照護成效評估聯盟（ICHOM）執行長布萊特（Jennifer L. Bright）簽署合作協議。台灣原創的SNQ品質認證機制，正式成為ICHOM亞洲第一個合作夥伴。 透過此次合作，SNQ將已發展成熟的品質認證機制，更進一步結合ICHOM知名的「病人回報成果量測」（PROMs）標準，讓本土醫療品質系統與國際標準接軌，不但能提升台灣醫療品質的國際曝光度，並使台灣醫界共同成就的SNQ醫療品質認證，在全球展現更大影響力。 陳維昭表示，台灣醫療28年來歷經SNQ國家品質標章機制，水準持續提高，與國際趨勢並進，此次和ICHOM合作，SNQ的經驗與方法能給更多國際醫療體系參考，並使獲SNQ標章的團隊被世界看見。 SNQ累計2,900件認證 打造台灣最具代表性的品質體系 自1998年創立至今，SNQ已完成超過2,900件跨領域認證，涵蓋特色醫療、醫事服務、管理、護理、長照與社區服務等。SNQ匯聚百位以上醫界專家，以「結構→過程→結果」三階...
-

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which continues to show clinically meaningful deep and durable efficacy with predictable and manageable safety observed to date in relapsed or refractory multiple myeloma (RRMM) patients who had received at least three prior lines of therapy. These new...
-

Orca Bio Presents New Clinical Data on Orca-T® in Older Patients Using Reduced Intensity Conditioning Plus New Analyses from the Precision-T Phase 3 Study at the 67th ASH Annual Meeting

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio today announced new data presented on its lead investigational allogeneic T-cell immunotherapy, Orca-T, at the 67th ASH Annual Meeting....
-

NMDP℠ Demonstrates Scientific Leadership in Expanding Patient Access to Lifesaving Cell Therapy at ASH 2025

MINNEAPOLIS--(BUSINESS WIRE)--New research from NMDP, a global nonprofit leader in cell therapy, and conducted by CIBMTR® (Center for International Blood and Marrow Transplant Research®) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla., demonstrates that patients receiving allogeneic transplantation using more deeply mismatched unrelated donors (MMUD), followed by post-transplant chemotherapy, can achieve outcomes comparable to those receiving tran...
-

Genetix Participates in the American Society of Hematology’s (ASH) Exclusive Press Program & Shares Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced their participation in the American Society of Hematology’s (ASH) exclusive press program ahead of the 67th ASH annual meeting in Orlando, Florida (December 6-9, 2025). Genetix’s abstract Accelerating access to gene therapy: Lessons from commercial implementation in sickle cell disease and transfusion-dependent thalassemia was selected by the ASH Program Committee as one of the meeting’s most impactful datasets sub...
-

Mice Model Market Trends and Growth Opportunities by Segment & Region 2025-2032 - Transformative Innovations in Genetic Engineering Propel Mice Model Research in Oncology and Rare Diseases - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Mice Model Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering. The mice model market is experiencing robust growth, with projected expansion from USD 1.61 billion in 2024 to USD 3.11 billion by 2032, driven by a compound annual growth rate (CAGR) of 8.60%. This market research report explores the pioneering advances, critical drivers, and significant innovations redefining the landscape of mice model research, particularly in th...
-

Encoded Therapeutics Presents Positive Interim Efficacy Data from Initial Dose Levels of Phase 1/2 Trials Evaluating ETX101 Gene Therapy in Dravet Syndrome

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today announced positive interim results from its ongoing POLARIS clinical development program evaluating ETX101 in children with SCN1A+ Dravet syndrome. The data will be featured in an oral presentation at the American Epilepsy Society (AES) Annual Meeting today and again tomorrow in a poster session. The POLARIS program...
-

Mango Sciences Announces Partnership With ImmunoACT to Bring the World’s First Bridge Financing Plan and Value-Based Offering for CAR-T Therapy for Cancer Patients in India

BENGALURU, India--(BUSINESS WIRE)--Mango Sciences, Inc., announced a strategic partnership with ImmunoAdoptive Cell Therapy (ImmunoACT)....
-

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying medicine for Dravet syndrome. These data were presented at the 2025 American Epilepsy Society (AES)...
-

Natera Acquires Foresight Diagnostics

AUSTIN, Texas & BOULDER, Colo.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera has completed a transaction to acquire Foresight. Foresight is a cancer diagnostics company and CLIA-registered laboratory. The company’s circulating tumor DNA (ctDNA)-based MRD tests leverage its patented PhasED-Seq™ technology, targetin...